ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag stock market neuroscience evolution

a mockup of an at-home COVID-19 test in development
Top Technical Advances of 2020
Shawna Williams | Dec 18, 2020 | 3 min read
The pandemic spurred innovation in a variety of ways, from CRISPR-based diagnostics to cell biology benchwork at home.
Undaunted By Skittish 1992, Biotech Experts Express Optimism About New Year's Potential
Susan L-J Dickinson | Jan 10, 1993 | 8 min read
Executives and analysts see industry perking up, thanks to increases in product flow and supportive legislation The past year was a tumultuous one for the biotechnology industry, according to corporate executives and industry analysts. During 1992, the unprecedented level of financing that had been available in 1990 and 1991 virtually disappeared. Public biotech companies saw their stock lose nearly half its value from highs in January to lows at midyear. Landmark legislative decisions in fa
2018 Top 10 Innovations
The Scientist | Dec 1, 2018 | 10+ min read
Biology happens on many levels, from ecosystems to electron transport chains. These tools may help spur discoveries at all of life's scales.
Your Body Is Teeming with Weed Receptors
Megan Scudellari | Jul 16, 2017 | 10+ min read
And the same endocannabinoid system that translates marijuana's buzz-inducing compounds into a high plays crucial roles in health and disease outside the brain.
Cutting the Wire
Jeffrey M. Perkel | Dec 1, 2014 | 8 min read
Optical techniques for monitoring action potentials
Horse sense
Lisa A. Fortier | Jan 7, 2009 | 3 min read
A new book explores the impact of equines on early American energy and transportation technology
Clinical Trial Reversals Forcing Biotech Firms To Refine Strategy
Susan Dickinson | Sep 18, 1994 | 7 min read
Under pressure to reap return on investment, companies are seeking ways to ensure success in designing drug tests This past July, Synergen Inc. suspended clinical trials of its anti-inflammatory drug candidate, Antril--being tested to fight sepsis--for lack of efficacy. Faced with the setback to its $100 million-plus investment, the Boulder, Colo.-based biotech was forced to lay off more than half its work force and shut down two
Clinical Trial Reversals Forcing Biotech Firms To Refine Strategy
Susan Dickinson | Sep 18, 1994 | 7 min read
Under pressure to reap return on investment, companies are seeking ways to ensure success in designing drug tests This past July, Synergen Inc. suspended clinical trials of its anti-inflammatory drug candidate, Antril--being tested to fight sepsis--for lack of efficacy. Faced with the setback to its $100 million-plus investment, the Boulder, Colo.-based biotech was forced to lay off more than half its work force and shut down two
Automated Colony Pickers Evolve
Helen Dell(hdell@the-scientist.com) | Jul 3, 2005 | 6 min read
Everyone knows that the first genome sequencing projects took years of work and represent the combined product of tens of thousands of individual fragments.
Radioimmunoassay: A Proven Performer In the Bio Lab
Rebecca Krumm | May 15, 1994 | 9 min read
AUTHOR: REBECCA KRUMM, pp.17 Date: May 16,1994 SUPPLIERS OF RADIOIMMUNOASSAY KITS, REAGENTS, AND SUPPLIES The following companies offer radioimmunoassay supplies and equipment. Please contact the companies directly for more information concerning specific products. Advanced Chemtech 5609 Fern Valley Rd. Louisville, Ky. 40228 (502) 969-0000 Fax: (502) 968-1000 AMAC Inc. 160B Larrabee Rd. Westbrook, Maine 04092 (207) 854-0426 Fax

Run a Search

ADVERTISEMENT